Bavarian Nordic
BAVA.COBavarian Nordic is a publicly traded vaccine specialist with a firm focus on developing and manufacturing life-saving immunizations. The company has demonstrated strong commercial momentum, particularly in its Travel Health business, and has been a key supplier of a non-replicating smallpox/mpox vaccine for global public health stockpiles. Its strategy leverages a fully integrated model from R&D through manufacturing to address infectious disease threats.
BAVA.CO · Stock Price
Historical price data
AI Company Overview
Bavarian Nordic is a publicly traded vaccine specialist with a firm focus on developing and manufacturing life-saving immunizations. The company has demonstrated strong commercial momentum, particularly in its Travel Health business, and has been a key supplier of a non-replicating smallpox/mpox vaccine for global public health stockpiles. Its strategy leverages a fully integrated model from R&D through manufacturing to address infectious disease threats.
Technology Platform
Specialized in the Modified Vaccinia Ankara (MVA) platform, a non-replicating viral vector used as a backbone for developing safe and effective vaccines against various infectious diseases.
Pipeline
66| Drug | Indication | Stage | Watch |
|---|---|---|---|
| IMVAMUNE® | Vaccination | Approved | |
| VAXCHORA (Cholera Vaccine, Live, Oral) | Cholera (Disorder) | Approved | |
| PROSTVAC-V + PROSTVAC-F + GM-CSF + Placebo | Prostate Cancer Metastatic | Phase 3 | |
| PXVX0200 + placebo | Cholera | Phase 3 | |
| MVA-BN standard regimen + MVA-BN standard regimen (Administe... | Neonate | Phase 3 |
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Bavarian Nordic competes with large vaccine players like GSK, Sanofi, and Pfizer in travel health and RSV, and with Emergent BioSolutions in the smallpox/mpox space. Its differentiation is built on its specialized MVA platform, integrated manufacturing, and proven track record in fulfilling government public health contracts.